 "USFDA completes inspection at SMS Pharma's Kandivalasa unit")
Hyderabad-based SMS Pharmaceuticals Limited today informed the stock exchanges that the US Food and Drug Administration (USFDA) inspection of unit-7 located at Kandivalasa village in the north coastal district of Vizianagarm in Andhra Pradesh has been successfully completed in the last week.
Last year the company said it was investing Rs 400 crore in the Vizianagaram plant in addition to Rs 350 crore in another unit located in the neighboring district Srikakulam as part of its expansion plans in AP.
The company, which is into active pharmaceuticals ingredients (APIs) and contract manufacturing activity, has a USFDA approved plant apart from three other manufacturing facilities in Hyderabad.
It may be recalled that the company had sold its USFDA-approved plant in Visakhapatnam to the American generics company Mylan Pharmaceuticals in 2012.